Collegium Pharmaceutical, Inc.
COLL
$27.72
$0.672.48%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 631.45M | 599.25M | 576.65M | 566.92M | 566.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 631.45M | 599.25M | 576.65M | 566.92M | 566.77M |
| Cost of Revenue | 83.53M | 79.91M | 79.39M | 78.94M | 79.72M |
| Gross Profit | 547.92M | 519.33M | 497.26M | 487.98M | 487.05M |
| SG&A Expenses | 186.03M | 160.33M | 153.56M | 148.42M | 150.71M |
| Depreciation & Amortization | 165.30M | 144.35M | 139.86M | 142.81M | 145.76M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 434.87M | 384.59M | 372.81M | 370.17M | 376.19M |
| Operating Income | 196.58M | 214.66M | 203.84M | 196.75M | 190.58M |
| Income Before Tax | 98.57M | 128.01M | 141.21M | 129.91M | 75.73M |
| Income Tax Expenses | 29.38M | 39.42M | 41.32M | 36.62M | 27.58M |
| Earnings from Continuing Operations | 69.19 | 88.59 | 99.89 | 93.29 | 48.16 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 69.19M | 88.59M | 99.89M | 93.29M | 48.16M |
| EBIT | 196.58M | 214.66M | 203.84M | 196.75M | 190.58M |
| EBITDA | 365.74M | 362.77M | 347.36M | 343.16M | 339.83M |
| EPS Basic | 2.14 | 2.74 | 3.06 | 2.83 | 1.47 |
| Normalized Basic EPS | 2.64 | 3.10 | 2.85 | 2.56 | 2.30 |
| EPS Diluted | 1.85 | 2.42 | 2.68 | 2.50 | 1.28 |
| Normalized Diluted EPS | 2.11 | 2.46 | 2.25 | 2.02 | 1.92 |
| Average Basic Shares Outstanding | 129.10M | 129.32M | 130.81M | 132.99M | 134.99M |
| Average Diluted Shares Outstanding | 162.10M | 163.27M | 165.16M | 167.63M | 160.51M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |